Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...2728293031323334353637...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Factors Affecting a Short-Term Response to Anti-VEGF Therapy in Diabetic Macular Edema. (Pubmed Central) -  Jan 29, 2021   
    The number of microaneurysms in the pericapillary network was higher (p = 0.0007) in poor (2.7 ± 2.2) than in good (1.4 ± 2.0) responders. Baseline glycemic control and macular ischemia may be associated with the short-term response to intravitreal anti-VEGF injections.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Rayoqta (abicipar pegol) / Molecular Partners, AbbVie
    Journal:  Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration. (Pubmed Central) -  Jan 28, 2021   
    Abicipar pegol has been proven to be an emerging, promising anti-VEGF agent in the management of w-AMD. The possibility of adopting a quarterly regimen would allow a decrease in treatment burden and improve patient compliance; however, further larger-scale studies should better characterize abicipar pegol clinical efficacy over longer follow-up periods.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Journal:  Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography. (Pubmed Central) -  Jan 21, 2021   
    This cohort study included optical coherence tomography (OCT) volumes from study participants with early or intermediate AMD in the fellow eye in the HARBOR (A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration) trial...In this study, drusen and HRF represented imaging biomarkers of disease progression in AMD, demonstrating distinct topographic patterns over time that differed between eyes progressing to MNV, eyes progressing to MA, or eyes without disease progression. Automated localization and precise quantification of these factors may help to develop reliable methods of predicting future disease progression.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    New trial:  OCTA and Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) -  Jan 18, 2021   
    P,  N=60, Completed, 
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal, HEOR:  Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China. (Pubmed Central) -  Jan 16, 2021   
    The incremental cost-effectiveness ratios were 129,397 CNY/QALY and -12,774 CNY/QALY for intravitreal aflibercept versus laser photocoagulation and ranibizumab, respectively. Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation; it was considered as a dominant strategy when compared with ranibizumab.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs. (Pubmed Central) -  Jan 16, 2021   
    Thirty consecutive eyes (25 patients) were identified that were treated with ≥3 intravitreal bevacizumab (IVB) and/or ranibizumab (IVR) injections prior to treatment with ≥3 IVA injections...Early switch saved $22,884/eye and produced an additional 0.027 QALYs. Early conversion to IVA optimizes vision outcomes and results in lower overall treatment expenditures.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab. (Pubmed Central) -  Jan 14, 2021   
    Additionally, the microparticles presented minimal toxicity to human retinal cells in vitro with over 90% cell viability and they also exhibited good injection feasibility through 31-gauge needle in an ex vivo porcine eye model. These results warrant further studies to evaluate the clinical potential for treating posterior ophthalmic diseases as well as other conditions or injuries requiring long-term local drug administration.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal, Monotherapy:  Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy. (Pubmed Central) -  Jan 13, 2021   
    The mean number of intravitreal ranibizumab or intravitreal aflibercept injections over 24 months was 5.7 ± 4.5 in the intravitreal ranibizumab-photodynamic therapy group and 12.2 ± 3.8 in the intravitreal aflibercept group (p < .0001). The intravitreal ranibizumab-photodynamic therapy combination therapy was noninferior to fixed-dosing intravitreal aflibercept monotherapy in improving visual acuity and required fewer injections.
  • ||||||||||  lemon balm extract (ALS-L1023) / Hanmi, AngioLab
    Trial completion date, Trial primary completion date, Combination therapy:  Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD (clinicaltrials.gov) -  Jan 13, 2021   
    P2,  N=126, Enrolling by invitation, 
    The intravitreal ranibizumab-photodynamic therapy combination therapy was noninferior to fixed-dosing intravitreal aflibercept monotherapy in improving visual acuity and required fewer injections. Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Journal:  Foveal Eversion: A Possible Biomarker of Persistent Diabetic Macular Edema. (Pubmed Central) -  Jan 10, 2021   
    Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Foveal eversion is associated with worse clinical and morphological outcomes in DME.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Re: Comparison of pain during intravitreal dexamethasone, ranibizumab and aflibercept injection. (Pubmed Central) -  Jan 1, 2021   
    In addition to reviewing known elements of intravitreal VEGF toxicity, the cases presented encompass renal pathology data supporting that intravitreal VEGF blockade can result in deleterious systemic and renal pathological disorders. No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Therapeutic positioning and use of intravitreal ranibizumab and aflibercept () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1025;    
    The algorithm is well implemented in our hospital achieving a rational ophthalmic drug use. IVR and IVA are effective and safe, with better complete responses than those described in PCT.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. (Pubmed Central) -  Dec 23, 2020   
    Finally, glaucomatous patients injected with VEGF traps (ranibizumab or aflibercept) due to either AMD or DME comorbidity, showed a significant reduction of RGC axon fiber layer thickness, consistent with the plausible reduction of the VEGF autocrine stimulation of RGCs. Our results provide evidence of the autocrine neuroprotective function of VEGF on RGCs is crucially involved to preserve injured RGCs such as in glaucomatous patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Intravitreal steroids for macular edema in diabetes. (Pubmed Central) -  Dec 22, 2020   
    Any benefits should be weighed against IOP elevation, the use of IOP-lowering medication and, in phakic patients, the progression of cataract. The need for glaucoma surgery is also increased, but remains rare.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal, HEOR:  Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a U.S. perspective: analysis of 2-year Protocol T data. (Pubmed Central) -  Dec 18, 2020   
    P3
    However, the superior anatomical result was observed in dexamethasone implant group during this short follow-up. Aims: Protocol T (NCT01627249) was a head-to-head study conducted by the Diabetic Retinopathy Clinical Research Network that compared intravitreal aflibercept, bevacizumab, and ranibizumab for the treatment of diabetic macular edema (DME)...This analysis suggests that aflibercept is not cost-effective versus ranibizumab for patients with DME, regardless of baseline vision.
  • ||||||||||  Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    NEOVASCULAR GLAUCOMA IN A YOUNG MALE PATIENT WITH EALES’ DISEASE. CASE REPORT AND LITERATURE OVERVIEW () -  Dec 18, 2020 - Abstract #EGS2020EGS_9;    
    Five years after the onset of the disease and after having been treated with 3 intravitreal injections (ranibizumab), segmental scatter photocoagulation, 2 anti-glaucoma agents and a left eye cataract extraction, he was referred to our clinic complaining of unilateral ocular pain and vision disturbances...The ocular pressure was 38mmHg while under treatment with a brinzolamide and timolol combination... Minimally invasive PPV followed by OR combined with a valve insertion as an anti-glaucoma procedure resulted to a better outcome regarding the patient’s clinical profile.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    MICROIMPULSE CYCLOPHOTOCOAGULATION IN COMBINED NEOVASCULAR GLAUCOMA TREATMENT () -  Dec 18, 2020 - Abstract #EGS2020EGS_8;    
    The treatment was combined, consisting of intraocular VEGF-inhibitors (ranibizumab) injection with the following transscleral diode-laser CPC in microimpulse mode after 7-14 days using «Cyclo G6 Glaucoma Laser System» (IRIDEX, USA) with a power of 2000 mWt, exposure of 160 sec... The combined treatment of the patients with a secondary NVG, consisting of intraocular VEGF-inhibitors injection and microimpulse cyclophotocoagulation is an effective and safe method of IOP Decrease.